FY2025 EPS Forecast for PTC Therapeutics Cut by Analyst

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Equities researchers at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for PTC Therapeutics in a note issued to investors on Monday, February 3rd. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn ($3.26) per share for the year, down from their previous forecast of ($2.84). Cantor Fitzgerald has a “Overweight” rating and a $113.00 price objective on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.56) per share.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, beating the consensus estimate of ($1.54) by $0.15. The company had revenue of $196.79 million during the quarter, compared to the consensus estimate of $173.51 million. During the same period in the prior year, the company earned ($1.76) earnings per share.

Several other research firms have also recently weighed in on PTCT. Barclays upped their price objective on shares of PTC Therapeutics from $45.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 3rd. Morgan Stanley upgraded PTC Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $45.00 to $67.00 in a research note on Friday, December 13th. Royal Bank of Canada upgraded shares of PTC Therapeutics from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $39.00 to $63.00 in a report on Tuesday, December 3rd. UBS Group boosted their price objective on shares of PTC Therapeutics from $47.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Finally, Citigroup lifted their price objective on PTC Therapeutics from $26.00 to $32.00 and gave the stock a “sell” rating in a research note on Wednesday, December 4th. Three analysts have rated the stock with a sell rating, four have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $57.85.

PTC Therapeutics Stock Up 1.2 %

Shares of PTC Therapeutics stock opened at $49.99 on Wednesday. The stock has a market capitalization of $3.86 billion, a price-to-earnings ratio of -8.42 and a beta of 0.62. The company has a 50-day simple moving average of $46.23 and a two-hundred day simple moving average of $40.12. PTC Therapeutics has a twelve month low of $23.58 and a twelve month high of $54.16.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PTCT. Charles Schwab Investment Management Inc. increased its stake in PTC Therapeutics by 7.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 706,730 shares of the biopharmaceutical company’s stock valued at $26,220,000 after buying an additional 47,902 shares during the last quarter. Two Sigma Advisers LP increased its position in shares of PTC Therapeutics by 10.3% during the third quarter. Two Sigma Advisers LP now owns 429,842 shares of the biopharmaceutical company’s stock valued at $15,947,000 after acquiring an additional 40,300 shares during the last quarter. Intech Investment Management LLC bought a new stake in PTC Therapeutics during the third quarter worth $698,000. Quest Partners LLC boosted its position in PTC Therapeutics by 433.9% in the third quarter. Quest Partners LLC now owns 22,359 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 18,171 shares during the last quarter. Finally, State Street Corp grew its stake in PTC Therapeutics by 5.4% in the 3rd quarter. State Street Corp now owns 2,899,040 shares of the biopharmaceutical company’s stock valued at $107,554,000 after purchasing an additional 149,700 shares during the period.

Insider Buying and Selling at PTC Therapeutics

In related news, VP Mark Elliott Boulding sold 85,600 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $52.26, for a total value of $4,473,456.00. Following the completion of the sale, the vice president now directly owns 92,389 shares of the company’s stock, valued at approximately $4,828,249.14. This represents a 48.09 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Lee Scott Golden sold 810 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total transaction of $36,725.40. Following the completion of the sale, the executive vice president now owns 79,849 shares of the company’s stock, valued at approximately $3,620,353.66. The trade was a 1.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 211,737 shares of company stock valued at $10,920,687. Company insiders own 5.50% of the company’s stock.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.